- 065/ New generation BIOMIMETIC and customized IMPLANTS for BONE ENGINEERING NEW GENERATION BIOMIMETIC AND CUSTOMIZED IMPLANTS FOR BONE ENGINEERING Brussels, 9 th March 2015 COST Action – MP 1301 – Chair : Dr Francis Cambier

- 065/ New generation BIOMIMETIC and customized IMPLANTS for BONE ENGINEERING What context ?  With a predicted ageing population and increasing expectations regarding quality of life in old age, there is an ever increasing demand for procedures such as total hip replacements, bone reconstructions, and spinal fusions, resulting from conditions such as joint cartilage degeneration and osteoporosis.  Due to the gap between academic R&D and commercial production, and between materials scientists and clinicians, medical application of these new materials will never be possible unless companies and medics are involved in the development.  This COST Action, NEWGEN, aims at creating the seed for the European research and industry collaboration, combining basic knowledge from academic laboratories, R&D centers, medical units from hospitals, and a significant number of companies New generation BIOMIMETIC and customized IMPLANTS for BONE ENGINEERING

- 065/ New generation BIOMIMETIC and customized IMPLANTS for BONE ENGINEERING Some figures  One third of the population is more than 60 years old in 2010  hip replacements in Europe /year  invasive spinal fusions in Europe /year  More than operations involving bone grafting or bone substitutes performed around the world / year  Orthopedic biomaterials market : ~ $8 billions (grow rate 5%)  US: 42 %, Europe: 31 %

- 065/ New generation BIOMIMETIC and customized IMPLANTS for BONE ENGINEERING The need of cooperation Design Biomaterials preparation Processing CharacterisationsFunctionalization In vitro / In vivo testings Medical assessment Fabrication Strong interactions between : R&D Hospital units Producers Surgical operation

- 065/ New generation BIOMIMETIC and customized IMPLANTS for BONE ENGINEERING Lack of communications between R&D, Hospital units and Industry  Unique opportunity to link European researchers to industries and end-users

- 065/ New generation BIOMIMETIC and customized IMPLANTS for BONE ENGINEERING – Establish a structured coordination, helping in the development of the right products. – R&D increasing performance – Increase of competitiveness of European companies Objectives, benefits, impacts  Concrete achievements – Multi-partners projects, mainly on new bioactive and customized bone implants, incorporating every aspect of the whole value chain (including H2020 projects) – Attraction of an Asian company to Europe – Dissemination (1 collective book, papers, Web site)

- 065/ New generation BIOMIMETIC and customized IMPLANTS for BONE ENGINEERING  Consortium of partners – 29 COST countries + 3 non-COST countries (USA, Canada, Australia ) – 141 partners – 50% of the consortium members are companies, surgeons/medical units and research centers

- 065/ New generation BIOMIMETIC and customized IMPLANTS for BONE ENGINEERING How it works COST Office Management committee WG 1WG 3WG 4WG 2 Chair/Vice-chair 4 WG Leaders At least 1 by COST country 1 by non-COST participant Members 1 WG Leader – 1 vice leader Transversal activities (web page feeding, events organisation, communication, STSMs…) Each WG will consist of partners from academic institutes, industries and medical units Core group Chair, VC, WG leaders GH STSM, Dissemination, Web

- 065/ New generation BIOMIMETIC and customized IMPLANTS for BONE ENGINEERING The tools  Core group meetings  WG meetings  Scientific workshops  MC meetings (to approve the suggestions)  STSM – selection is difficult: 1 st quality, ECI, inclusiveness policy countries, gender balance, etc.  Summer schools  Dissemination – grants, book, papers, etc.

- 065/ New generation BIOMIMETIC and customized IMPLANTS for BONE ENGINEERING Is it easy ?  How to get the support of COST: – Pre-proposal (4 pages, web) 30 rd Sept 2012  2 experts  eligible (10 th Oct 2012)  ok for a full proposal (end Nov 2012) – Proposal (40 pages) end Jan 2013  experts – Selection to present (orally)  DC Hearing in Brussels (40 people, mid March 2013) – Decision of DC (9 th April 2013)  administrative details to be completed – Decision by Cost Office and CSO (end of May 2013)  beginning of signature of MoU by the countries – Kick Off Meeting  2 nd Oct 2013 (starting date)  The language: – Everything is in the Vademecum (including a 2 pages lexicon) – Examples : WG, STSM, LOS, ECI (was ESR), GH, MC, AO, SO, KOM, CNC, SC, EB, (CSO, DC ?), etc.  The role of the grant holder: – Follow the rules (Vademecum) while scientists do not understand (or are not willing to do that)  A difficulty and advantage: – loss of control of the players (members of MC) – but it is a part of the interest  opening to new countries, etc.

- 065/ New generation BIOMIMETIC and customized IMPLANTS for BONE ENGINEERING Thank you for your attention Conclusion: A very nice experience